DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• DBV Technologies S.A. has received an average consensus rating of "Moderate Buy" from five research firms, with a 12-month price target of $14.75.
• The stock has experienced significant analyst activity, including a sell rating from Goldman Sachs and a strong buy rating from Lifesci Capital.
• In its latest quarterly earnings report, DBV Technologies missed EPS estimates, reporting ($1.55) compared to the expected ($0.21), while its revenue for the quarter was significantly higher than anticipated.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $14.75.

A number of analysts recently issued reports on DBVT shares. The Goldman Sachs Group upgraded DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a research note on Thursday, May 29th. Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. JMP Securities restated a "market outperform" rating and issued a $21.00 target price on shares of DBV Technologies in a research note on Thursday, June 26th. Lifesci Capital upgraded DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. Finally, Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors have recently bought and sold shares of the stock. Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies during the 2nd quarter valued at about $340,000. Octagon Capital Advisors LP purchased a new stake in DBV Technologies in the 2nd quarter worth approximately $9,315,000. MPM Bioimpact LLC bought a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,649,000. Adage Capital Partners GP L.L.C. bought a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,659,000. Finally, Vivo Capital LLC bought a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,659,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Stock Down 0.8%

DBVT stock traded down $0.08 during midday trading on Wednesday, hitting $9.87. The company's stock had a trading volume of 18,275 shares, compared to its average volume of 32,958. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $12.78. The stock's 50-day moving average price is $9.73 and its 200 day moving average price is $8.49. The stock has a market cap of $270.44 million, a price-to-earnings ratio of -2.07 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The firm had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. As a group, equities analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.